Allegria Therapeutics raises funding

Allegria Therapeutics develops mast cell-targeting therapies for allergic and inflammatory diseases. It coordinates the MastCURe consortium, backed by EUR 1.3 million in Eurostars funding, to tackle chronic urticaria.

Announced on
Round
Grant
Amount
Amount not disclosed
Location
canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic